Navigation Links
Trubion Announces Presentation of Positive TRU-016 Data at ASCO
Date:6/2/2008

TRU-016 Produces Significant Anti-Tumor Activity and Long-Term Tumor

Regression in Pre-Clinical Studies

SEATTLE, June 2 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced presentation of positive pre-clinical data showing that Trubion's TRU-016 has potent anti-tumor activity and induces significant long-term tumor eradication in a human tumor xenograft model in which rituximab failed to induce durable responses. TRU-016 is Trubion's proprietary CD37-targeted therapy in development for B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL).

ASCO Abstract 3074

TRU-016, a small modular immunopharmaceutical (SMIPTM) candidate, targets the CD37 antigen on human B cells. Data from both in vivo and in vitro studies presented at the American Society of Clinical Oncology (ASCO) 2008 Annual Meeting showed TRU-016 has potent anti-tumor activity and induces significant long-term tumor eradication in a human tumor xenograft model in which rituximab failed to induce durable responses. Moreover, TRU-016 treatment produced anti-tumor activity that resulted in increased survival and a significant delay in tumor growth in NHL xenografts.

These data were presented during a poster session at the ASCO Annual Meeting on June 1, 2008, from 2-4 p.m. CDT. The poster is available on the investor section of Trubion's Web site: http://investors.trubion.com/events.cfm.

"Data from this study, combined with data from previous studies, reinforce our belief that TRU-016's novel mechanism of action may provide patients with a potent new therapeutic option for the treatment
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
2. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
3. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
4. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
5. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
6. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
7. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
8. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
9. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
11. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Synereca Pharmaceutics, ... novel orally active drugs that restore or ... today a $1.4 million convertible debt financing. ... life sciences accelerator Accele Biopharma, Inc., led ... a nationally recognized private not-for-profit corporation focused ...
(Date:9/16/2014)... Alberta , Sept. 16, 2014  Wearable ... billion industry in less than two years, producing ... the way. A huge opportunity exists for leveraging ... Vivametrica ( http://vivametrica.com/our-video/ ) introduced a first-of-its-kind wearable ... based on years of clinical research linking activity ...
(Date:9/16/2014)... , Sept. 16, 2014  Eli Lilly ... AstraZeneca today announced an agreement to co-develop and ... (BACE) inhibitor currently in development as a potential ... of Alzheimer,s disease is characterized by the accumulation ... an enzyme associated with the development of beta-amyloid. ...
Breaking Medicine Technology:Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4
... NEW YORK, July 19, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0574366/World-Healthcare-UPS-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices This ... healthcare UPS market, examining drivers and restraints ...
... INDIANAPOLIS, July 19, 2011 Data were presented today ... semagacestat, including data from a 32 week follow-up period ... a gamma secretase inhibitor that had been studied as ... provided patient outcomes from the active treatment portion of ...
Cached Medicine Technology:World Healthcare UPS Markets 2World Healthcare UPS Markets 3World Healthcare UPS Markets 4World Healthcare UPS Markets 5World Healthcare UPS Markets 6Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research 2Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research 3Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research 4
(Date:9/16/2014)... CA (PRWEB) September 16, 2014 According to ... player David Wilson has retired after aggravating a neck injury ... and was then discovered to have spinal stenosis as well, ... many adults and can lead to symptoms such as back ... play again after surgery to repair the disc, but recently ...
(Date:9/16/2014)... September 16, 2014 According to ... Research "Latin America Home Healthcare Market (By Device ... Devices, Mobility Assist Devices and Medical Supplies; By ... Therapy and Unskilled Home Healthcare Services) - Industry ... - 2020" the Latin American Home Healthcare market ...
(Date:9/16/2014)... 2014 Today The FSH Society, a world ... Evening of Song,” featuring luminary pianist Steven Blier and two-time ... September 29, 2014 at the Tappan Hill Mansion, located on ... FSH Society is proud to welcome Blier, who performs each ... for FSHD research. , FSHD, one of the most prevalent ...
(Date:9/16/2014)... 16, 2014 Luke Sniewski, Claire Robbie ... a 14-month journey around the world to celebrate cultural ... project, titled ‘Million Ways to Live’, will take them ... the healthy lifestyles of amazing, unique and diverse people. ... the documentary series will focus on how individuals apply ...
(Date:9/16/2014)... September 16, 2014 According to a ... global authority in medical device market research, the market ... $750 million in the U.S . and ... PEG placement kits, PEG replacement tubes, DPEJ tubes, PEG/J ... into low-profile balloon tubes, low-profile non-balloon tubes, nasogastric and ...
Breaking Medicine News(10 mins):Health News:NFL Injuries Put Spotlight on Spinal Health 2Health News:NFL Injuries Put Spotlight on Spinal Health 3Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Health News:Pianist Steven Blier and Grammy Award-Winner Sylvia McNair to Perform Together for FSH Society Benefit 2Health News:Pianist Steven Blier and Grammy Award-Winner Sylvia McNair to Perform Together for FSH Society Benefit 3Health News:Launched by Luke Sniewski and Claire Robbie, Million Ways to Live is an International Documentary Series on Healthy Living in Different Cultures 2Health News:Launched by Luke Sniewski and Claire Robbie, Million Ways to Live is an International Documentary Series on Healthy Living in Different Cultures 3Health News:Over 17 Million Enteral Feeding Device Placement Procedures is Expected to be Performed in the U.S. and Europe in 2020: Market Led by Covidien, Kimberly-Clark and Abbott 2Health News:Over 17 Million Enteral Feeding Device Placement Procedures is Expected to be Performed in the U.S. and Europe in 2020: Market Led by Covidien, Kimberly-Clark and Abbott 3
... passive smoke could face a higher heart disease risk, says ... second hand smoke exposure through levels of a nicotine by-product ... on the participants' recall of exposure. ,However, in ... of Nottingham, and other researchers measured the level of cotinine ...
... linked to many of the same health problems as tobacco ... wheeze, according to a new study by researchers at Yale ... widely used illicit drug in the United States, and abuse ... published in today’s Archives of Internal Medicine. First author Jeanette ...
... treating atrial fibrillation, a common irregular heart rhythm that ... of Medicine in St. Louis have developed and tested ... surgical procedure that has had the best long-term cure ... procedure is termed Cox-maze IV, and the surgeons believe ...
... migrant birds will be outstaying their welcome in north and central ... has called for tougher measures on bird flu prevention, especially in ... this time, there is an increase in transportation of livestock and ... is predominant during this season. , Yin ...
... that aids patients who suffer from persistent iron overload has ... ,Patients suffering from a rare genetic condition or conditions ... Generally these people are given a painful infusion at nights ... ,But the new drug Exjade is an oral ...
... stress hormone cortisol can have positive effects in certain ... cortisol in the bloodstream, can weaken the immune system ... evidence that cortisol given near in time to a ... impact. ,Psychologists are especially interested in what ...
Cached Medicine News:Health News:Long-term Marijuana Smoking Leads to Respiratory Complaints 2Health News:Surgeons Develop Simpler Way to Cure Atrial Fibrillation 2Health News:Extra Cortisol Protects Women’s Mood Under Stres 2
Steinmann Pins are available in six point styles ranging from 5/64 to 3/16 in. diameters, in standard 9 in. (230 mm) lengths with threaded and smooth tips. Material: DePuy certified stainless steel. ...
... is the only approved radiolucent stand-alone implant ... with the proven reliability of the BAK ... System is constructed of radiolucent, carbon-fiber reinforced ... radiologic visualization, providing a new level of ...
... (Western Blot): The Genetic Systems HIV-1 Western ... the detection of antibodies to HIV-1. The solid ... HIV-1 grown in the CEM cell line. Use ... of HLA Class ll antigens, helps reduce cross ...
... HIV-1 RNA Assay (bDNA) delivers unmatched precision and ... providing physicians with viral load values they can ... and at other critical decision points - without ... need more reasons to choose VERSANT HIV bDNA, ...
Medicine Products: